Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;14(6):1093-1103.
doi: 10.1007/s12072-020-10112-3. Epub 2020 Dec 8.

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis

Benedikt Simbrunner  1   2   3   4   5 , Georg Semmler  1   2 , Alexander Stadlmann  1   2   6 , Bernhard Scheiner  1   2 , Philipp Schwabl  1   2   5 , Rafael Paternostro  1   2 , Theresa Bucsics  1   2 , David Bauer  1   2 , Ernst Eigenbauer  7 , Matthias Pinter  1 , Albert-Friedrich Stättermayer  1 , Peter Quehenberger  8 , Rodrig Marculescu  8 , Michael Trauner  1 , Mattias Mandorfer  1   2 , Thomas Reiberger  9   10   11   12   13
Affiliations

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis

Benedikt Simbrunner et al. Hepatol Int. 2020 Dec.

Abstract

Background and aims: The liver plays a key role in the storage, metabolism and homeostasis of fat-soluble vitamins. We investigated the relation of Vitamin(Vit)A/D/E serum levels with severity of liver disease and portal hypertension (PHT).

Methods: VitA/D/E serum levels were assessed in 234 patients with advanced chronic liver disease (ACLD, i.e. hepatic venous pressure gradient [HVPG] ≥ 6 mmHg). Patients with hepatocellular carcinoma, pre-/post-hepatic PHT, TIPS or liver transplantation were excluded.

Results: Most patients were male (n = 153; 65%) with a median age of 57.6 (49.7-64.5) years. Thirty-two (14%) patients had HVPG 6-9 mmHg, 66 (28%) 10-15 mmHg, and 136 (58%) ≥ 16 mmHg, respectively. VitD deficiency (25-OH-vitamin-D <50 nmol/L) was found in 133 (57%) with higher prevalence in Child-Turcotte-Pugh (CTP)-C: 85% vs. B: 66% vs. A: 47% (p < 0.001). VitD levels displayed significant but weak correlations with hepatic dysfunction and PHT. VitE levels were normal in 227 (97%) patients and displayed no relevant association with hepatic dysfunction or PHT. Only 63 (27%) patients had normal (>1.05 µmol/L) VitA levels, while 58 (25%) had mild (0.70-1.04 µmol/L), 71 (30%) moderate (0.35-0.69 µmol/L), and 42(18%) severe(<0.35 µmol/L) VitA deficiency. VitA correlated with HVPG (Rho = -0.409), CTP score (Rho = -0.646), and serum bile acid levels (Rho = -0.531; all p < 0.001). The prevalence of decompensated ACLD (dACLD) continuously increased with severity of VitA deficiency (no: 40% vs. mild: 51% vs. moderate: 67% vs. severe: 91% had dACLD; p < 0.001). CTP score (per point; OR 2.46; 95%CI 1.80-3.37; p <0.001), age (per year; OR 0.95; 95%CI 0.92-0.98; p = 0.001) and elevated bile acid levels(>10 µmol/L; OR 3.62; 95%CI 1.61-8.14; p = 0.002) were independently associated with VitA deficiency.

Conclusion: VitA and VitD but not VitE deficiencies are highly prevalent in ACLD. VitA deficiency strongly correlates with hepatic dysfunction, PHT and bile acid levels and is associated with decompensated ACLD.

Trial registration number: NCT03267615.

Keywords: ACLD; Cirrhosis; Hepatic decompensation; Hepatic venous pressure gradient.

PubMed Disclaimer

Conflict of interest statement

BeSi received travel support from AbbVie and Gilead. BeSc received travel support from Abbvie and Gilead. PS received speaking honoraria from Bristol-Myers Squibb and Boehringer-Ingelheim, consulting fees from PharmaIN, and travel support from Falk and Phenex Pharmaceuticals. DB received travel support from AbbVie and Gilead. TB received speaker honoraria from BMS, travel support from Abbvie, BMS, and Gilead; travel grant, financial award/grant from Medis. MP is an investigator for Bayer, BMS, Lilly, and Roche; he received speaker honoraria from Bayer, BMS, Eisai, and MSD; he is a consultant for Bayer, BMS, Ipsen, Eisai, Lilly, MSD, and Roche; he received travel support from Bayer and BMS. MT received speaker fees from BMS, Falk Foundation, Gilead, Intercept and MSD; advisory board fees from Albireo, BiomX, Boehringer Ingelheim, Falk Pharma GmbH, Genfit, Gilead, Intercept, MSD, Novartis, Phenex and Regulus. He further received travel grants from Abbvie, Falk, Gilead and Intercept and unrestricted research grants from Albireo, Cymabay, Falk, Gilead, Intercept, MSD and Takeda. MM has served as a speaker and/or consultant and/or advisory board member for AbbVie, Bristol-Myers Squibb, Gilead, W.L. Gore & Associates and Janssen. TR received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche. GS, AFS, AS, EE, and RP declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Vitamin A, D, and E serum levels in patients stratified by (a, b, c) Child-Turcotte-Pugh (CTP) stage and (d, e, f) hepatic venous pressure gradient (HVPG). Different colours in the background indicate ranges between cut-offs for Vitamin A, D, and E deficiencies as specified in the methods section. VitA vitamin A, VitD vitamin D, VitE vitamin E, HVPG hepatic venous pressure gradient, CTP Child-Turcotte-Pugh, ns not significant, (*) p < 0.05, (***) p < 0.001
Fig. 2
Fig. 2
Prevalence of compensated and decompensated advanced chronic liver disease in patients stratified by the presence and severity of vitamin A, D, and E deficiency. VitA vitamin A, VitD vitamin D, VitE vitamin E, cACLD compensated advanced chronic liver disease, dACLD decompensated advanced chronic liver disease
Fig. 3
Fig. 3
Correlation between vitamin A serum levels and Model for End-stage Liver Disease (MELD) score, bile acid serum levels, and enhanced liver fibrosis (ELF) score. VitA vitamin A, MELD Model for end-stage liver disease, BA bile acids, ELF enhanced liver fibrosis score
Fig. 4
Fig. 4
Comparison of coagulation parameters in patients stratified by vitamin A quintiles. Green colour in the background indicates normal ranges for AT-III and Protein C activity, respectively. Q1–Q5 quintile 1–5; INR international normalized ratio; AT-III antithrombin-III, (***) p < 0.001
See this image and copyright information in PMC

References

    1. Di Ciaula A, et al. Bile acid physiology. Ann Hepatol. 2017;16(Suppl. 1):s4–s14. doi: 10.5604/01.3001.0010.5493. - DOI - PubMed
    1. Grune T, et al. β-Carotene is an important vitamin A source for humans. J Nutr. 2010;140(12):2268S–2285S. doi: 10.3945/jn.109.119024. - DOI - PMC - PubMed
    1. Haaker MW, Vaandrager AB, Helms JB. Retinoids in health and disease: a role for hepatic stellate cells in affecting retinoid levels. Biochim Biophys Acta. 2020;1865:158674. doi: 10.1016/j.bbalip.2020.158674. - DOI - PubMed
    1. Blaner WS, et al. Hepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage. Biochim Biophys Acta. 2009;1791(6):467–473. doi: 10.1016/j.bbalip.2008.11.001. - DOI - PMC - PubMed
    1. Testerink N, et al. Replacement of retinyl esters by polyunsaturated triacylglycerol species in lipid droplets of hepatic stellate cells during activation. PLoS ONE. 2012;7(4):e34945. doi: 10.1371/journal.pone.0034945. - DOI - PMC - PubMed

Associated data